HLY78
Based on 15 publication(s) in Google Scholar
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research.
For research use only. We do not sell to patients.
- Purity: 98.44%
- CAS No.: 854847-61-3
- Formula: C17H17NO2
- Molecular Weight:267.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Cytoskeleton Compound Library
HY-L060
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Antidepressant Compound Library
HY-L108
-
Osteogenesis Compound Library
HY-L131
-
Cell Death Library
HY-L162
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) HLY78
More- Adv Funct Mater. 2024 Apr 25;34(17):2309866. [Abstract]
- Adv Sci (Weinh). 2025 Sep 9:e13476. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2026;20(5):101741. [Abstract]
- Neurosci Bull. 2020 Oct;36(10):1171-1181. [Abstract]
- Ecotoxicol Environ Saf. 2025 Dec:308:119482. [Abstract]
- Cancer Gene Ther. 2023 Apr;30(4):596-607. [Abstract]
- Toxicology. 2024 Dec:509:153960. [Abstract]
- Brain Res Bull. 2020 Sep:162:107-114. [Abstract]
- J Bioenerg Biomembr. 2026 Apr 22;58(1):19. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar:508:117718. [Abstract]
- J Cancer. 2021 Oct 28;12(24):7334-7348. [Abstract]
- Oncol Lett. 2021 Oct;22(4):688. [Abstract]
- Curr Med Sci. 2024 Aug;44(4):789-798. [Abstract]
- Int Ophthalmol. 2023 May;43(5):1687-1699. [Abstract]
- Dis Markers. 2022 Jul 11:2022:7926483. [Abstract]
Customer Validation & Images
-
IF
-
IF
-
WB
Biological Activity
Wnt/β-catenin[1]
HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway[2].
HLY78 (20 μM, 0-48 h) significantly increases the colony formation ability by 2.78-fold and 2.88-fold for HGC-27 and AGS cells compared with the controls[3].
HLY78 (20 μM, 0-48 h) elevates the migration ability of HGC-27 and AGS cells[3].
HLY78 significantly increases TNKS expression, which is ameliorated by Dihydroartemisinin (HY-N0176)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague-Dawley rats (280-310 g, n=9/group, SAH model)[2]
-
Dosage:0, 0.2, 0.6, and 1.8 mg/kg
-
Administration:Intranasal injection, once, at 1 h post-SAH (subarachnoid hemorrhage)
-
Result:Significantly attenuated the short-term and long-term neurobehavioral deficits, as well as the neuronal apoptosis after SAH at 0.6 mg/kg. Successfully delivered into the brain via intranasal administration at 0.6 mg/kg and was sufficient to significantly increase the phosphorylation of LRP6. Reversed the changes of the Bcl-2, Bax, and cleaved caspase 3 levels.
Chemical Information
-
CAS No. 854847-61-3
-
Appearance Solid
-
Molecular Weight 267.32
-
Formula C17H17NO2
-
Color Off-white to light yellow
-
SMILES
CCC1=CC=CC2=C1N(CC3=CC4=C(C=C32)OCO4)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Adv Funct Mater
Metabolically Glycoengineered Neural Stem Cells Boost Neural Repair After Cardiac Arrest. [Abstract]2024 Apr 25;34(17):2309866. PMID: 39071865 -
Adv Sci (Weinh)
Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury. [Abstract]2025 Sep 9:e13476. PMID: 40923460 -
Cell Mol Gastroenterol Hepatol
Mast Cells Inhibit Stem Cell-driven Epithelial Repair in Inflammatory Bowel Disease via Suppressing Wnt/lrp6/β-Catenin Signaling Pathway. [Abstract]2026;20(5):101741. PMID: 41616821 -
Neurosci Bull
HLY78 Attenuates Neuronal Apoptosis via the LRP6/GSK3β/β-Catenin Signaling Pathway After Subarachnoid Hemorrhage in Rats. [Abstract]2020 Oct;36(10):1171-1181. PMID: 32562163
HLY78 purchased from MedChemExpress. Usage Cited in: Neurosci Bull. 2020 Oct;36(10):1171-1181. [Abstract]
Effects of HLY78 on neuronal apoptosis at 24 h after SAH. Representative Western blot bands of Bcl-2, Bax, and cleaved caspase.
-
Ecotoxicol Environ Saf
Asiaticoside ameliorates pyrimethanil-induced autophagy-dependent liver injury by suppressing CRHR1. [Abstract]2025 Dec:308:119482. PMID: 41338089 -
Cancer Gene Ther
miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2. [Abstract]2023 Apr;30(4):596-607. PMID: 36494581
HLY78 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2023 Apr;30(4):596-607. [Abstract]
Both HLY78 and BRD5631 significantly abrogate the effects of miR-219-5p on SKOV3 and SKOV3/DDP cell invasion (fig E) and migration (fig F).
HLY78 purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2023 Apr;30(4):596-607. [Abstract]
Both HLY78 and BRD5631 significantly abrogate the effect of miR-219-5p on SKOV3 and SKOV3/DDP cell apoptosis.
-
Toxicology
Prenatal exposure to low doses of benzophenone-3 elicits disruption of cortical vasculature in fetuses through perturbations in Wnt/β-catenin signaling correlating with depression-like behavior in offspring mice. [Abstract]2024 Dec:509:153960. PMID: 39343157 -
Brain Res Bull
HLY78 protects blood-brain barrier integrity through Wnt/β-catenin signaling pathway following subarachnoid hemorrhage in rats. [Abstract]2020 Sep:162:107-114. PMID: 32565130 -
J Bioenerg Biomembr
A study on the mechanism of IGFBP-3 affecting autophagy to partially protect against inflammatory damage in inflammatory bowel disease. [Abstract]2026 Apr 22;58(1):19. PMID: 42018045 -
Toxicol Appl Pharmacol
EP300 promotes cervical cancer progression through a Wnt/β-catenin-dependent HIF-1α signaling axis. [Abstract]2026 Mar:508:117718. PMID: 41565034 -
J Cancer
Targeting ADAR1 suppresses progression and peritoneal metastasis of gastric cancer through Wnt / β-catenin pathway. [Abstract]2021 Oct 28;12(24):7334-7348. PMID: 35003354 -
Oncol Lett
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer. [Abstract]2021 Oct;22(4):688. PMID: 34457043 -
Curr Med Sci
Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells. [Abstract]2024 Aug;44(4):789-798. PMID: 38926329 -
Int Ophthalmol
β-asarone attenuates the proliferation, migration and enhances apoptosis of retinoblastoma through Wnt/β-catenin signaling pathway. [Abstract]2023 May;43(5):1687-1699. PMID: 36372820 -
Dis Markers
miR-26a-5p Suppresses Wnt/ β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC. [Abstract]2022 Jul 11:2022:7926483. PMID: 35860691
Solvent & Solubility
DMSO : 26 mg/mL (97.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (398 KB)
- English - EN (398 KB)
- Français - FR (398 KB)
- Deutsch - DE (398 KB)
- Norwegian - NO (398 KB)
- Español - ES (398 KB)
- Swedish - SV (398 KB)
- Italian - IT (398 KB)
- Korean - KR (398 KB)
- Portuguese - PT (398 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang S, et al. Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction. Nat Chem Biol. 2013 Sep;9(9):579-85. [Content Brief]
[2]. Luo X, et al. HLY78 Attenuates Neuronal Apoptosis via the LRP6/GSK3β/β-Catenin Signaling Pathway After Subarachnoid Hemorrhage in Rats. Neurosci Bull. 2020 Oct;36(10):1171-1181. [Content Brief]
[3]. Ma Y, et al. Dihydroartemisinin suppresses proliferation, migration, the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer. Oncol Lett. 2021 Oct;22(4):688. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7408 mL | 18.7042 mL | 37.4083 mL | 93.5209 mL |
| 5 mM | 0.7482 mL | 3.7408 mL | 7.4817 mL | 18.7042 mL | |
| 10 mM | 0.3741 mL | 1.8704 mL | 3.7408 mL | 9.3521 mL | |
| 15 mM | 0.2494 mL | 1.2469 mL | 2.4939 mL | 6.2347 mL | |
| 20 mM | 0.1870 mL | 0.9352 mL | 1.8704 mL | 4.6760 mL | |
| 25 mM | 0.1496 mL | 0.7482 mL | 1.4963 mL | 3.7408 mL | |
| 30 mM | 0.1247 mL | 0.6235 mL | 1.2469 mL | 3.1174 mL | |
| 40 mM | 0.0935 mL | 0.4676 mL | 0.9352 mL | 2.3380 mL | |
| 50 mM | 0.0748 mL | 0.3741 mL | 0.7482 mL | 1.8704 mL | |
| 60 mM | 0.0623 mL | 0.3117 mL | 0.6235 mL | 1.5587 mL | |
| 80 mM | 0.0468 mL | 0.2338 mL | 0.4676 mL | 1.1690 mL |
HLY78 Related Classifications
HY-122816 Related Classifications
Powered by Bioz